SCHEMBL25214650

SCHEMBL25214650

C=C(Cc1nc(C2(c3ccc(Br)cc3)CC2)no1)C(=O)OCC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.36
▸ MEN1 O00255 5/20 0.36
▸ HTT P42858 1/20 0.36
▸ ALOX5AP P20292 5/20 0.35
▸ LMNA P02545 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ RBP1 P09455 2/20 0.32
▸ SLC6A3 Q01959 1/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ AKR1B1 P15121 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27022955 0.90 KMT2A (0.46) KMT2AMEN1HTTALOX5APLMNA
SCHEMBL25254226 0.87 MEN1 (0.34) KMT2AMEN1HTTALOX5APLMNA
SCHEMBL23578175 0.87 KMT2A (0.39) KMT2AMEN1HTTALOX5APLMNA
SCHEMBL25223995 0.85 S1PR1 (0.36) KMT2AMEN1HTTMAPT
SCHEMBL23578419 0.84 KMT2A (0.37) KMT2AMEN1HTTALOX5APLMNA
SCHEMBL25258144 0.84 PDE2A (0.36) KMT2AMEN1HTTALOX5APLMNA
SCHEMBL25805322 0.78 KMT2A (0.40) KMT2AMEN1HTTALOX5APLMNA
SCHEMBL23588185 0.76 KMT2A (0.39) KMT2AMEN1HTTALOX5APLMNA
SCHEMBL23588183 0.76 KMT2A (0.39) KMT2AMEN1HTTALOX5APLMNA
SCHEMBL23578427 0.76 KMT2A (0.39) KMT2AMEN1HTTALOX5APLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459908-B2 Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties SITRYX THERAPEUTICS LIMITED (GB) 2025-11-04 — — US claimed
US-20240018111-A1 ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2024-01-18 — — US claimed
EP-4192821-A1 ALPHA,BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2023-06-14 — — EP claimed
US-12459908-B2 Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties SITRYX THERAPEUTICS LIMITED (GB) 2025-11-04 — — US disclosed
US-20240018111-A1 ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2024-01-18 — — US disclosed
US-20240018111-A1 ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2024-01-18 — — US disclosed
US-20240018111-A1 ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2024-01-18 — — US disclosed
EP-4192821-A1 ALPHA,BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2023-06-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459908-B2 Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties PTGS1, PTGER1, PTGES2 KMT2A 3983/4885MEN1 2557/4885HTT 3664/4885
US-20240018111-A1 ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES PTGS1, PTGER1, PTGES2 KMT2A 3983/4885MEN1 2557/4885HTT 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback